Headquartered in Brussels, Belgium, SERB is an independent leading European niche specialty pharma company focused on niche branded prescription medicines, with operating offices in Belgium, France, the United Kingdom, and Luxembourg. SERB has a strong focus on therapeutic areas such as critical and emergency care, neurology, diagnostics and endocrinology. The company has experienced an exceptional growth and stability in the portfolio, with revenues increasing from €3m to €65m between 2001 and 2016 and a significant geographical expansion including an attractive development in the US. This outstanding development follows a strategy focusing on targeted acquisitions of niche products with high potential growth and the organic growth of SERB portfolio.
Jérémie Urbain will remain at the helm of the company and will re-invest significantly, together with the incumbent management team. Charterhouse will continue to support management’s product acquisition strategy as well as the expansion of the platform into new geographies and therapeutic areas.
Charterhouse capitalised on its significant prior experience of the European pharma sector, following the acquisitions of Cooper and Vemedia in the OTC space in 2015 and 2016 and DOC Generici in the generics market in 2013. SERB marks the fourth investment in Charterhouse Capital Partners X.
Jérémie Urbain decided to open SERB’s capital in order to accelerate its development, commenting: ”SERB has entered a new phase of its development in the context of a dynamic market favorable to acquisitions. I am delighted to welcome Charterhouse, a respected financial partner with an excellent track-record and ability to dedicate significant financial and human resources to achieve SERB’s ambitious goals.”
Pierre de Sarrau, Partner at Charterhouse, said: “We are delighted to partner with excellent managers like Jérémie Urbain and his team. We will build on SERB’s success and particularly on their strength in emergency care and diagnostics, by supporting the acceleration of the internationalization of the company and continuing to acquire additional products and complementary businesses.”
Closing of the transaction is subject to the finalization of the legal transactional documents and the agreements from regulatory and antitrust authorities, including local antitrust authorities.
List of participants
Edmond de Rothschild Corporate Finance : Arnaud Petit (Managing Director), Alexandre Aron-Brunetière (Associate), Arthur Pignot (Analyst) Debt Advisory : Gregory Fradelizi (Managing Director)